Company Proteomics International Laboratories Limited

Equities

PIQ

AU000000PIQ0

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Proteomics International Laboratories Limited

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

PROTEOMICS INTERNATIONAL LABORATORIES LIMITED

Market Closed - Australian S.E. Other stock markets 01:22:03 2024-04-26 am EDT			5-day change	1st Jan Change
1.095 ^AUD	+0.46%		+0.46%	+22.35%

Mar. 25	Proteomics International Signs Agreement with University of Oxford for Endometriosis Study	MT
Mar. 19	Proteomics Says PromarkerD's US Launch Delayed	MT

Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bio-analytical services. The Company specializes in proteomics, the study of the structure and function of proteins. The Company focuses on developing and commercializing diagnostic tests for chronic diseases. The Company operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. The PromarkerD test system is a blood test that assess the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Its Analytical Services includes a proteomics-based technology platform, used to test, and validate the protein composition of varied range of products.

AUD in Million	2022	Weight	2023	Weight	Delta
Analytical Services 98.0 %	-	-	1	98.0 %	-
Licensing 2.0 %	-	-	0	2.0 %	-

AUD in Million	2022	Weight	2023	Weight	Delta
Australia and New Zealand 80.9 %	1	81.7 %	1	80.9 %	-51.45%
United States 12.4 %	0	10.4 %	0	12.4 %	-41.46%
India 4.9 %	0	0.4 %	0	4.9 %	+478.20%
Europe 1.7 %	0	7.3 %	0	1.7 %	-88.42%
Southeast Asia 0.0 %	0	0.1 %	0	0.0 %	-94.20%

Managers	Title	Age	Since
Richard Lipscombe FOU	Founder	-	14-06-08
Jacqueline Gray DFI	Director of Finance/CFO	-	21-07-11
Kirsten Peters CTO	Chief Tech/Sci/R&D Officer	-	-
Bringans Scott CTO	Chief Tech/Sci/R&D Officer	-	-
Michael LeFauve PRN	Corporate Officer/Principal	-	-
Vik Malik PRN	Corporate Officer/Principal	-	21-05-31
Pearl Tan PRN	Corporate Officer/Principal	-	12-12-31
John Morrison PRN	Corporate Officer/Principal	-	-
Karen Logan SEC	Corporate Secretary	-	-

Members of the board	Title	Age	Since
Paul House BRD	Director/Board Member	-	17-11-21
Robyn Elliott BRD	Director/Board Member	63	21-11-15
Richard Lipscombe FOU	Founder	-	14-06-08
Ian Moore BRD	Director/Board Member	-	16-10-13
Neville Gardiner CHM	Chairman	-	21-11-15

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	122,334,721	90,367,126 ( 73.87 %)	0	73.87 %

Name	Equities	%	Valuation
Richard Lipscombe 12.54 %	16,417,125	12.54 %	12 M $
FIL Investment Management (Hong Kong) Ltd. 6.035 %	7,900,000	6.035 %	6 M $
John Sutherland Dunlop 2.945 %	3,855,188	2.945 %	3 M $
Dissel Dirk Charles Hawker Van 1.746 %	2,285,842	1.746 %	2 M $
Himstedt Family 1.632 %	2,136,471	1.632 %	2 M $
Randolph Resources Pty Ltd. 1.489 %	1,949,000	1.489 %	1 M $
Sparrow Holdings Pty Ltd. 1.467 %	1,920,500	1.467 %	1 M $
Altor Capital Management Pty Ltd. 1.268 %	1,660,000	1.268 %	1 M $
McCusker Holdings Pty Ltd. 1.146 %	1,500,000	1.146 %	1 M $
Lisa Floan 1.041 %	1,363,235	1.041 %	1 M $

Proteomics International Laboratories Ltd.

QEII Medical Centre 6 Verdun Street

6009, Perth

http://www.proteomics.com.au

address Proteomics International Laboratories Limited(PIQ)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.095 AUD

Average target price

1.38 AUD

Spread / Average Target

+26.03%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PROTEOMICS INTERNATIONAL LABORATORIES LIMITED	+22.35%	93.47M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs